BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for ...
ENPP1 Deficiency is a progressively debilitating condition of the vasculature, soft tissue, and skeleton with a prevalence of approximately 1 in 64,000 pregnancies worldwide. Although ENPP1 Deficiency ...
Welltica+ on MSN
Can damaged kidneys heal? New study offers hope
An existing drug may also prove useful in treating kidney damage.
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ:INZY) updated its global development strategy for INZ-701, a treatment for ENPP1 ...
Songnan Wang (left) and Lingyin Li (right) analyzing the results of breast cancer lung metastasis experiments. The plate on the left shows lung metastasis of breast cancer cells expressing ENPP1 and ...
Inozyme Pharma, Inc. announced that Dr. Kurt Gunter, the company's Senior Vice President and Chief Medical Officer, will present data on the Expanded Access Program for their therapeutic candidate INZ ...
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...
ISM5939 is being advanced as a therapy for cancer immunotherapy and the treatment of Hypophosphatasia. ISM5939 is a potentially best-in-class oral ENPP1 inhibitor with a novel molecular structure.
Scientists have successfully restored hearing in animal models of ENPP1 deficiency, a genetic disease in which individuals lack an enzyme essential for bone and blood vessel health. The rare disorder ...
We also report on new understanding of how Ebola infections may persist in the brain and other organs for months, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results